載入...
THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is the superselective inhibitor of the androgen receptor (AR), which blocks several stages of the AR signal path. The drug showed significant e...
Na minha lista:
| Main Authors: | , , |
|---|---|
| 格式: | Artigo |
| 語言: | Russo |
| 出版: |
Remedium Group LLC
2017-06-01
|
| 叢編: | Медицинский совет |
| 主題: | |
| 在線閱讀: | https://www.med-sovet.pro/jour/article/view/1894 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|